Related Experiment Videos
Antinociceptive effect of sumatriptan in mice
1Pharmacology Division, Panjab University, Chandigarh, India.
Indian Journal of Experimental Biology
|June 5, 1999
Summary
The antimigraine drug sumatriptan, a serotonin 5-HT1A agonist, reduces pain in mice. This pain relief involves the central cholinergic system, not opioid pathways.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Sumatriptan is a 5-HT1A agonist primarily used for migraines.
- The antinociceptive (pain-relieving) mechanisms of 5-HT1A agonists are not fully understood.
Purpose of the Study:
- To investigate the antinociceptive effect of sumatriptan.
- To explore the involvement of opioid and cholinergic systems in sumatriptan-induced antinociception.
Main Methods:
- Acetic acid-induced writhing test in mice.
- Administration of sumatriptan, naloxone, physostigmine, and atropine.
- Comparison with another 5-HT1A agonist, buspirone.
Main Results:
- Sumatriptan demonstrated dose-dependent antinociception.
- Naloxone did not reverse sumatriptan's effect, indicating no opioid involvement.
- Physostigmine potentiated, while atropine blocked, sumatriptan's antinociception.
- Buspirone also produced antinociception, potentiated by physostigmine and blocked by atropine.
- Buspirone potentiated sumatriptan's analgesic effect.
Conclusions:
- 5-HT1A agonists, like sumatriptan, likely produce antinociception.
- This effect appears to be mediated through the modulation of the central cholinergic system.
- The findings suggest a non-opioid mechanism for 5-HT1A agonist-induced pain relief.